Glemep^®

Glimepiride

Description

Glimepiride is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Glimepiride. Administration of Glimepiride can lead to increase sensitivity of peripheral tissues to insulin. After oral administration, Glimepiride is completely (100%) absorbed from Gl tract. When Glimepiride is given with meals, the mean Tmax is slightly increased (12%) and the mean Cmax and AUC are slightly decreased. Glimepiride is completely metabolized by oxidative biotransformation after oral dose. When 14C-Glimepiride is given orally, approximately 60% of the total radioactivity is recovered in the urine in 7 days and 80-90% of the metabolites are recovered in the urine.

Indications
Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and excercise or in conjunction with and oral hypoglycaemic agent.

Supply
Glemep^® 2mg Tablet: Each box contains 3×10 tablets.